Research on breast cancer, and more specifically, metastatic breast cancer (mBC), is critical in helping us better understand this disease. While widespread knowledge of mBC is still limited, there are studies that look specifically at the detection, prognosis and treatment of this type of breast cancer. Similarly, clinical trials on metastatic breast cancer are crucial in helping researchers improve the current standard of care. Below are some of the latest research and some currently recruiting clinical trials on metastatic breast cancer.
Latest Research
130 archival tumor samples were collected from 103 breast cancer patients in order to assess the incidence and clinical implications of mutations in the ESR1 gene. Results indicate that there are clinical implications for the ESR1 mutation in both newly diagnosed metastatic and local recurrence of endocrine-treated breast cancer.
In this podcast, Dr. Mark D. Pegram discusses findings from the DESTINY-Breast01 clinical trial. This study showed a median progression-free survival (PFS) of 16.4 months for metastatic HER2+ breast cancer patients using trastuzumab deruxtecan. In discussing the study, Dr. Pegram also discusses the unique structure of this treatment.
Tucatinib (Tukysa) was recently approved for use in Canada. In this video, Dr. Kamran A. Ahmed discusses the role of this treatment in breast cancer-related brain metastases. While data suggests that tucatinib may help in managing patients with active brain metastases who haven’t gotten previous local therapy, little is known about how this drug can help in managing patients with small asymptomatic brain metastases.
CDK4/6 inhibitors (palbociclib (Ibrance), ribociclib (Kisqali), and abemaciclib (Verzenio)) have transformed the standard of care for treating HR+ metastatic breast cancer. In multiple phase 3 clinical trials, CDK4/6 inhibitors have led to improvements in median progression-free survival (PFS). Dr. Denise A. Yardley discusses the role of CDK4/6 inhibitors in metastatic breast cancer treatment and management.
Clinical Trials that are Currently Recruiting
Title of Study:
Treatment of Canadian Postmenopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy ± Targeted Therapy
Patient Population:
Advanced or Metastatic Breast Cancer
Location(s):
Montreal, QC
Contact Information:
Rosalia Santos
514-934-1934 ext. 44328
rosalia.santos@muhc.mcgill.ca
Click HERE for more information.
Title of Study:
A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer (BEGONIA)
Patient Population:
Advanced or Metastatic Triple Negative Breast Cancer
Location(s):
London, ON
Greenfield Park, QC
Contact Information:
AstraZeneca Clinical Study Information Center
1-877-240-9479
information.center@astrazeneca.com
Contact: AstraZeneca Cancer Study Locator Service
1-877-400-4656
AstraZeneca@emergingmed.com
Click HERE for more information.
Title of Study:
Palbociclib in Real World Practice
Patient Population:
Advanced or Metastatic Breast Cancer
Location(s):
Burnaby, BC
Mississauga, ON
Chicoutimi, QC
Contact Information:
Access contact information here.
Click HERE for more information.
Title of Study:
Phase 2 Study of SAR439859 Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer (AMEERA-3)
Patient Population:
Advanced or Metastatic Breast Cancer
Location(s):
Montreal, QC
Contact Information:
Dr Cristiano Ferrario, MD
514-340-8222 Ext. 4210
Mme Heather Gregory
514-340-8222 Ext. 26758
heather.gregory@ladydavis.ca
Click HERE for more information.
For more up-to-date research, visit ASCO or BreastCancer.org. For more clinical trials that are currently recruiting, you can visit the Clinical Trials Ontario website or the ClinicalTrials.gov website.
Receive updates by email 
